董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Douglas Williams | 男 | Director | 67 | 20.53万美元 | 1.65 | 2025-10-01 |
| Andrew Levin | 男 | Director | 48 | 7.91万美元 | 4.00 | 2025-10-01 |
| Judith Dunn | -- | Director | 63 | 8.97万美元 | 7.46 | 2025-10-01 |
| Stephen Thomas | 男 | Director | 36 | 7.91万美元 | 17.92 | 2025-10-01 |
| Alexander Cumbo | 男 | Director | 54 | 16.87万美元 | 0.44 | 2025-10-01 |
| Aoife Brennan | 女 | Director, President and Chief Executive Officer | 49 | 292.22万美元 | 未持股 | 2025-10-01 |
| Kimberlee Drapkin | 女 | Director | 57 | 17.06万美元 | 0.44 | 2025-10-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cindy Driscoll | 女 | Senior Vice President, Finance and Principal Accounting Officer | 59 | 未披露 | 未持股 | 2025-10-01 |
| Susan Altschuller | 女 | Chief Financial Officer and Treasurer | 43 | 115.14万美元 | 未持股 | 2025-10-01 |
| Aoife Brennan | 女 | Director, President and Chief Executive Officer | 49 | 292.22万美元 | 未持股 | 2025-10-01 |
董事简历
中英对照 | 中文 | 英文- Douglas Williams
-
Douglas Williams，董事长兼董事:DouglasE.Williams博士目前是Codiak BioSciences的总裁、首席执行官和董事会成员。2011年1月至2015年7月，他曾担任Biogen研究与开发的高管Vice President。他从ZymoGenetics公司加入Biogen公司，在那里他最近担任首席执行官兼董事会成员。此前，他曾担任生物技术行业的领导职务，包括西雅图遗传学公司（Seattle Genetics）的首席科学官兼研究与开发执行Vice President，以及安进公司（Amgen）的高级副总裁和华盛顿站点负责人。Williams博士十多年来在Immunex公司担任过一系列科学和高级领导职务，包括执行Vice President和首席技术官以及董事会成员。在他三十多年的生物技术行业职业生涯中，他在包括Enbrel，Tecfidera和Spinraza在内的几种新药的开发中发挥了作用。他曾任职众多生物技术公司的董事会，目前是Ovid Therapeutics公司、AC Immune公司的董事会成员。
Douglas Williams, Chairman and Director: Dr. Douglas E. Williams is currently the President, CEO and member of the Board of Directors of Codiak BioSciences. He was previously Biogen’s Executive Vice President, Research and Development, serving in this role from January 2011 to July 2015. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. During his more than thirty year career in the biotechnology industry he has played a role in the development of several novel drugs including Enbrel, Tecfidera, and Spinraza. He has served on the board of numerous biotechnology companies and is currently a member of the Board of Directors of Ovid Therapeutics, and AC Immune. - Douglas Williams，董事长兼董事:DouglasE.Williams博士目前是Codiak BioSciences的总裁、首席执行官和董事会成员。2011年1月至2015年7月，他曾担任Biogen研究与开发的高管Vice President。他从ZymoGenetics公司加入Biogen公司，在那里他最近担任首席执行官兼董事会成员。此前，他曾担任生物技术行业的领导职务，包括西雅图遗传学公司（Seattle Genetics）的首席科学官兼研究与开发执行Vice President，以及安进公司（Amgen）的高级副总裁和华盛顿站点负责人。Williams博士十多年来在Immunex公司担任过一系列科学和高级领导职务，包括执行Vice President和首席技术官以及董事会成员。在他三十多年的生物技术行业职业生涯中，他在包括Enbrel，Tecfidera和Spinraza在内的几种新药的开发中发挥了作用。他曾任职众多生物技术公司的董事会，目前是Ovid Therapeutics公司、AC Immune公司的董事会成员。
- Douglas Williams, Chairman and Director: Dr. Douglas E. Williams is currently the President, CEO and member of the Board of Directors of Codiak BioSciences. He was previously Biogen’s Executive Vice President, Research and Development, serving in this role from January 2011 to July 2015. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. During his more than thirty year career in the biotechnology industry he has played a role in the development of several novel drugs including Enbrel, Tecfidera, and Spinraza. He has served on the board of numerous biotechnology companies and is currently a member of the Board of Directors of Ovid Therapeutics, and AC Immune.
- Andrew Levin
-
Andrew Levin是Eliem的联合创始人，从2018年10月到2020年10月担任我们的首席执行官，自2019年2月以来担任我们的董事会主席。自2015年以来，Levin博士一直担任RA Capital Management，L.P.的投资团队的常务董事。此前，Levin博士曾担任H.I.G.BioVentures的副总裁，在此之前，他曾担任Clinton Health Access Initiative的药物科学总监。Levin博士拥有普林斯顿大学机械工程学士学位，麻省理工学院生物医学工程博士学位和哈佛医学院硕士学位。
Andrew Levin has served as a member of board of directors since September 2024. Previoly, Dr. Levin served as the President and Founder of Carnot Pharma from 2016 to 2022. Dr. Levin is also a Co Founder of Eliem Therapeutics, Inc. (now Climb Bio, Inc. (Nasdaq: CLYM)) where he served as Chief Executive Officer from October 2018 to October 2020, and has served on the board of directors since February 2019 and as Executive Chairman of the board of directors since February 2023. Since 2015, Dr. Levin has served as a Managing Director on the Investment Team at RA Capital Management, L.P. Previoly, Dr. Levin was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a BS in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachetts Institute of Technology and an MD from Harvard Medical School. - Andrew Levin是Eliem的联合创始人，从2018年10月到2020年10月担任我们的首席执行官，自2019年2月以来担任我们的董事会主席。自2015年以来，Levin博士一直担任RA Capital Management，L.P.的投资团队的常务董事。此前，Levin博士曾担任H.I.G.BioVentures的副总裁，在此之前，他曾担任Clinton Health Access Initiative的药物科学总监。Levin博士拥有普林斯顿大学机械工程学士学位，麻省理工学院生物医学工程博士学位和哈佛医学院硕士学位。
- Andrew Levin has served as a member of board of directors since September 2024. Previoly, Dr. Levin served as the President and Founder of Carnot Pharma from 2016 to 2022. Dr. Levin is also a Co Founder of Eliem Therapeutics, Inc. (now Climb Bio, Inc. (Nasdaq: CLYM)) where he served as Chief Executive Officer from October 2018 to October 2020, and has served on the board of directors since February 2019 and as Executive Chairman of the board of directors since February 2023. Since 2015, Dr. Levin has served as a Managing Director on the Investment Team at RA Capital Management, L.P. Previoly, Dr. Levin was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a BS in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachetts Institute of Technology and an MD from Harvard Medical School.
- Judith Dunn
-
Judith Dunn自2021年2月以来一直是我们的董事会成员。Dunn博士自2021年4月起担任FulcrumTherapeutics，Inc.的研发总裁从2018年3月到2021年4月，Dunn博士担任Atlas Ventures驻留企业家。从2010年到2018年，Dunn博士担任F.Hoffmann-La Roche临床开发副总裁。Dunn博士从2005年到2010年在Sepracor领导精神病学临床开发，从1997年到2005年在Pfizer担任研究和商业职位。Dunn博士拥有卫斯理大学神经生物学学士学位和罗切斯特大学神经生物学博士学位。
Judith Dunn,has been a member of board of directors since February 2021. Dr. Dunn currently serves as Entrepreneur in Residence at Atlas Venture, or Atlas, a venture capital firm. Since October 2023, Dr. Dunn has served as Head of R&D for Vima Tx, an Atlas portfolio company. From April 2021 to January 2023, Dr. Dunn served as President of Research and Development of Fulcrum Therapeutics, Inc., a biopharmaceutical company. From March 2018 to April 2021, Dr. Dunn served as Entrepreneur in Residence at Atlas. From 2010 to 2018, Dr. Dunn served as Vice President of Clinical Development for F. Hoffmann-La Roche. Dr. Dunn led Psychiatry Clinical Development at Sepracor from 2005 to 2010 and held research and commercial positions at Pfizer from 1997 to 2005. Dr. Dunn holds a B.S. in neurobiology from University of Rochester and a Ph.D. in Neurobiology from Wesleyan University. - Judith Dunn自2021年2月以来一直是我们的董事会成员。Dunn博士自2021年4月起担任FulcrumTherapeutics，Inc.的研发总裁从2018年3月到2021年4月，Dunn博士担任Atlas Ventures驻留企业家。从2010年到2018年，Dunn博士担任F.Hoffmann-La Roche临床开发副总裁。Dunn博士从2005年到2010年在Sepracor领导精神病学临床开发，从1997年到2005年在Pfizer担任研究和商业职位。Dunn博士拥有卫斯理大学神经生物学学士学位和罗切斯特大学神经生物学博士学位。
- Judith Dunn,has been a member of board of directors since February 2021. Dr. Dunn currently serves as Entrepreneur in Residence at Atlas Venture, or Atlas, a venture capital firm. Since October 2023, Dr. Dunn has served as Head of R&D for Vima Tx, an Atlas portfolio company. From April 2021 to January 2023, Dr. Dunn served as President of Research and Development of Fulcrum Therapeutics, Inc., a biopharmaceutical company. From March 2018 to April 2021, Dr. Dunn served as Entrepreneur in Residence at Atlas. From 2010 to 2018, Dr. Dunn served as Vice President of Clinical Development for F. Hoffmann-La Roche. Dr. Dunn led Psychiatry Clinical Development at Sepracor from 2005 to 2010 and held research and commercial positions at Pfizer from 1997 to 2005. Dr. Dunn holds a B.S. in neurobiology from University of Rochester and a Ph.D. in Neurobiology from Wesleyan University.
- Stephen Thomas
-
Stephen Thomas，自2024年6月起担任董事会成员。他自2023年11月起担任Sera Medicines LLC或Sera Medicines的首席执行官和董事，并自2024年3月起担任Starfish Medicines的首席执行官和董事，这两家公司都是私营生物制药公司。Thomas博士此前曾于2024年8月至2025年2月担任私营生物技术公司Navigator Medicines的首席执行官和董事，并于2023年11月至2024年6月担任私营生物制药公司Tenet Medicines，Inc.的首席执行官和董事，该公司被Climb Bio收购。2020年2月至2023年1月，Thomas博士担任ValenzaBio Inc.（或ValenzaBio）的首席科学官，该公司是一家私营生物制药公司，专注于开发针对自身免疫性疾病的抗体疗法。在加入ValenzaBio之前，Thomas博士曾于2018年9月至2020年2月在Cerecor，Inc.（现为Avalo Therapeutics）担任副总裁兼发现部门负责人。此前的2018年9月，Thomas博士与他人共同创立并担任Ichorion Therapeutics，Inc.的首席科学官，该公司是一家私营生物制药公司，该公司已被Cerecor公司收购。Thomas博士曾获得哥伦比亚大学化学哲学博士（有机合成&化学生物学）、哥伦比亚大学化学理学硕士（有机合成）以及Renesselaer理工学院化学理学学士学位。
Stephen Thomas,has been a member of board of directors since June 2024. He has served as Chief Executive Officer and a director of Sera Medicines LLC, or Sera Medicines, since November 2023, and as Chief Executive Officer and a director of Starfish Medicines since March 2024, which are both privately held biopharmaceutical companies. Dr. Thomas previously served as the Chief Executive Officer and a director of Navigator Medicines, a privately held biotechnology company, from August 2024 to February 2025, and as Chief Executive Officer and a director of Tenet Medicines, Inc., a privately held biopharmaceutical company from November 2023 to June 2024, which was acquired by Climb Bio. From February 2020 to January 2023, Dr. Thomas served as Chief Scientific Officer of ValenzaBio Inc., or ValenzaBio, a privately held biopharmaceutical company focused on developing antibody therapeutics for autoimmune diseases. Prior to his time at ValenzaBio, Dr. Thomas served as V.P., Head of Discovery at Cerecor, Inc. (now Avalo Therapeutics) from September 2018 to February 2020. Prior to September 2018, Dr. Thomas co-founded and served as Chief Scientific Officer of Ichorion Therapeutics, Inc., a privately held biopharmaceutical company, which was acquired by Cerecor Inc. Dr. Thomas received a Doctor of Philosophy in Chemistry (Organic Synthesis & Chemical Biology) from Columbia University, a Master of Science in Chemistry (Organic Synthesis) from Columbia University, and a Bachelor of Science in Chemistry from Renesselaer Polytechnic Institute. - Stephen Thomas，自2024年6月起担任董事会成员。他自2023年11月起担任Sera Medicines LLC或Sera Medicines的首席执行官和董事，并自2024年3月起担任Starfish Medicines的首席执行官和董事，这两家公司都是私营生物制药公司。Thomas博士此前曾于2024年8月至2025年2月担任私营生物技术公司Navigator Medicines的首席执行官和董事，并于2023年11月至2024年6月担任私营生物制药公司Tenet Medicines，Inc.的首席执行官和董事，该公司被Climb Bio收购。2020年2月至2023年1月，Thomas博士担任ValenzaBio Inc.（或ValenzaBio）的首席科学官，该公司是一家私营生物制药公司，专注于开发针对自身免疫性疾病的抗体疗法。在加入ValenzaBio之前，Thomas博士曾于2018年9月至2020年2月在Cerecor，Inc.（现为Avalo Therapeutics）担任副总裁兼发现部门负责人。此前的2018年9月，Thomas博士与他人共同创立并担任Ichorion Therapeutics，Inc.的首席科学官，该公司是一家私营生物制药公司，该公司已被Cerecor公司收购。Thomas博士曾获得哥伦比亚大学化学哲学博士（有机合成&化学生物学）、哥伦比亚大学化学理学硕士（有机合成）以及Renesselaer理工学院化学理学学士学位。
- Stephen Thomas,has been a member of board of directors since June 2024. He has served as Chief Executive Officer and a director of Sera Medicines LLC, or Sera Medicines, since November 2023, and as Chief Executive Officer and a director of Starfish Medicines since March 2024, which are both privately held biopharmaceutical companies. Dr. Thomas previously served as the Chief Executive Officer and a director of Navigator Medicines, a privately held biotechnology company, from August 2024 to February 2025, and as Chief Executive Officer and a director of Tenet Medicines, Inc., a privately held biopharmaceutical company from November 2023 to June 2024, which was acquired by Climb Bio. From February 2020 to January 2023, Dr. Thomas served as Chief Scientific Officer of ValenzaBio Inc., or ValenzaBio, a privately held biopharmaceutical company focused on developing antibody therapeutics for autoimmune diseases. Prior to his time at ValenzaBio, Dr. Thomas served as V.P., Head of Discovery at Cerecor, Inc. (now Avalo Therapeutics) from September 2018 to February 2020. Prior to September 2018, Dr. Thomas co-founded and served as Chief Scientific Officer of Ichorion Therapeutics, Inc., a privately held biopharmaceutical company, which was acquired by Cerecor Inc. Dr. Thomas received a Doctor of Philosophy in Chemistry (Organic Synthesis & Chemical Biology) from Columbia University, a Master of Science in Chemistry (Organic Synthesis) from Columbia University, and a Bachelor of Science in Chemistry from Renesselaer Polytechnic Institute.
- Alexander Cumbo
-
Alexander Cumbo，自2025年3月起担任董事会成员。Cumbo先生自2022年12月起担任生命科学公司Solid Biosciences Inc.的总裁兼首席执行官和董事。在此之前，Cumbo先生曾在2020年10月至2022年12月期间担任总裁兼首席执行官，并担任基因治疗公司AavantiBio，Inc.或AavantiBio的董事，当时Solid Bio收购了AavantiBio。从2013年1月至2020年10月，Cumbo先生在精准基因医学公司Sarepta Therapeutics, Inc.担任越来越重要的职务，最终担任执行副总裁和首席商务官。从2011年到2013年，Cumbo先生担任Vertex Pharmaceuticals Incorporated或福泰制药一家生物技术公司的销售和治疗教育副总裁，推出丙型肝炎的治疗药物Incivek。从2010年到2011年，他担任福泰制药的区域总监。在加入福泰制药之前，Cumbo先生曾在生物制药公司吉利德科学公司担任多个商业职务，为HIV、HBV和心血管领域的特许经营权提供支持。Cumbo先生自2022年6月起担任Verve Therapeutics董事会成员。Cumbo先生此前曾于2018年11月至2020年4月在Ra Pharmaceuticals, Inc.的董事会任职，该公司是一家临床阶段的生物制药公司，被布鲁塞尔UCB收购。Cumbo先生获得了奥本大学实验室技术理学学士学位。
Alexander Cumbo,has been a member of board of directors since March 2025. Mr. Cumbo has served as the President and Chief Executive Officer and as a director of Solid Biosciences Inc., a life sciences company, or Solid Bio, since December 2022. Prior to that, Mr. Cumbo served as the President and Chief Executive Officer and as a director of AavantiBio, Inc., or AavantiBio, a gene therapy company, from October 2020 to December 2022, when Solid Bio acquired AavantiBio. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, or Vertex, a biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo has served on the board of directors of Verve Therapeutics, Inc. since June 2022. Mr. Cumbo previously served on the Board of Directors of Ra Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University. - Alexander Cumbo，自2025年3月起担任董事会成员。Cumbo先生自2022年12月起担任生命科学公司Solid Biosciences Inc.的总裁兼首席执行官和董事。在此之前，Cumbo先生曾在2020年10月至2022年12月期间担任总裁兼首席执行官，并担任基因治疗公司AavantiBio，Inc.或AavantiBio的董事，当时Solid Bio收购了AavantiBio。从2013年1月至2020年10月，Cumbo先生在精准基因医学公司Sarepta Therapeutics, Inc.担任越来越重要的职务，最终担任执行副总裁和首席商务官。从2011年到2013年，Cumbo先生担任Vertex Pharmaceuticals Incorporated或福泰制药一家生物技术公司的销售和治疗教育副总裁，推出丙型肝炎的治疗药物Incivek。从2010年到2011年，他担任福泰制药的区域总监。在加入福泰制药之前，Cumbo先生曾在生物制药公司吉利德科学公司担任多个商业职务，为HIV、HBV和心血管领域的特许经营权提供支持。Cumbo先生自2022年6月起担任Verve Therapeutics董事会成员。Cumbo先生此前曾于2018年11月至2020年4月在Ra Pharmaceuticals, Inc.的董事会任职，该公司是一家临床阶段的生物制药公司，被布鲁塞尔UCB收购。Cumbo先生获得了奥本大学实验室技术理学学士学位。
- Alexander Cumbo,has been a member of board of directors since March 2025. Mr. Cumbo has served as the President and Chief Executive Officer and as a director of Solid Biosciences Inc., a life sciences company, or Solid Bio, since December 2022. Prior to that, Mr. Cumbo served as the President and Chief Executive Officer and as a director of AavantiBio, Inc., or AavantiBio, a gene therapy company, from October 2020 to December 2022, when Solid Bio acquired AavantiBio. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, or Vertex, a biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo has served on the board of directors of Verve Therapeutics, Inc. since June 2022. Mr. Cumbo previously served on the Board of Directors of Ra Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University.
- Aoife Brennan
-
Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceuticals, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. - Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
- Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceuticals, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
- Kimberlee Drapkin
-
Kimberlee Drapkin，自2025年3月起担任董事会成员。Drapkin女士最近于2023年8月至2024年3月担任Graphite Bio，Inc.的首席执行官。她此前分别于2015年8月和2013年2月担任Jounce Therapeutics，Inc.的首席财务官和财务主管，直至2023年5月。Drapkin女士还自2023年6月起担任Imugene Limited董事会成员、自2023年6月起担任Kineta公司董事会成员、自2022年4月起担任Acumen Pharmaceuticals，Inc.董事会成员。她此前曾于2023年7月至2024年3月在Graphite Bio，Inc.担任董事会成员，于2020年12月至2022年12月在Yumanity Therapeutics，Inc.担任董事会成员，于2019年2月至2020年12月在Proteostatis Therapeutics，Inc.担任董事会成员。Drapkin女士的职业生涯始于普华永道会计师事务所，是一名注册会计师，拥有巴布森学院会计学学士学位。
Kimberlee Drapkin,has been a member of board of directors since March 2025. Ms. Drapkin most recently served as the Chief Executive Officer of Graphite Bio, Inc. from August 2023 to March of 2024. She was previously the Chief Financial Officer and Treasurer of Jounce Therapeutics, Inc. from August 2015 and February 2013, respectively, until May 2023. Ms. Drapkin also serves on the boards of directors for Imugene Limited since June 2023, Kineta, Inc. since June 2023 and Acumen Pharmaceuticals, Inc. since April 2022. She previously served on the board of directors of Graphite Bio, Inc. from July 2023 to March 2024, Yumanity Therapeutics, Inc. from December 2020 to December 2022 and Proteostatis Therapeutics, Inc. from February 2019 through December 2020. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College. - Kimberlee Drapkin，自2025年3月起担任董事会成员。Drapkin女士最近于2023年8月至2024年3月担任Graphite Bio，Inc.的首席执行官。她此前分别于2015年8月和2013年2月担任Jounce Therapeutics，Inc.的首席财务官和财务主管，直至2023年5月。Drapkin女士还自2023年6月起担任Imugene Limited董事会成员、自2023年6月起担任Kineta公司董事会成员、自2022年4月起担任Acumen Pharmaceuticals，Inc.董事会成员。她此前曾于2023年7月至2024年3月在Graphite Bio，Inc.担任董事会成员，于2020年12月至2022年12月在Yumanity Therapeutics，Inc.担任董事会成员，于2019年2月至2020年12月在Proteostatis Therapeutics，Inc.担任董事会成员。Drapkin女士的职业生涯始于普华永道会计师事务所，是一名注册会计师，拥有巴布森学院会计学学士学位。
- Kimberlee Drapkin,has been a member of board of directors since March 2025. Ms. Drapkin most recently served as the Chief Executive Officer of Graphite Bio, Inc. from August 2023 to March of 2024. She was previously the Chief Financial Officer and Treasurer of Jounce Therapeutics, Inc. from August 2015 and February 2013, respectively, until May 2023. Ms. Drapkin also serves on the boards of directors for Imugene Limited since June 2023, Kineta, Inc. since June 2023 and Acumen Pharmaceuticals, Inc. since April 2022. She previously served on the board of directors of Graphite Bio, Inc. from July 2023 to March 2024, Yumanity Therapeutics, Inc. from December 2020 to December 2022 and Proteostatis Therapeutics, Inc. from February 2019 through December 2020. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.
高管简历
中英对照 | 中文 | 英文- Cindy Driscoll
Cindy Driscoll自2017年6月起担任我们的财务Vice President。Driscoll女士拥有超过25年的财务领导经验。在2017年6月加入Magenta之前，Driscoll女士于2011年6月至2017年6月在东海制药（Tokai Pharmaceuticals，Inc.，简称Tokai）工作，最近于2014年9月至2017年6月担任财务Vice President，负责该上市公司的所有财务和行政业务，包括支持其2014年首次公开募股。在加入东海制药之前，Driscoll女士还曾于2005年7月至2011年6月担任财务顾问，在此期间，她曾担任Gloucester Pharmaceuticals，Inc.（现为新基医药公司所有）和Transmolecular，Inc.（现为Morphotek所有）的财务总监，Inc.，并支持与收购两家公司相关的尽职调查工作。Driscoll女士在纽约州立大学奥斯威戈分校（State University of New York at Oswego）获得经济学本科学位，并在萨福克大学（Suffolk University）完成工商管理硕士学位。
Cindy Driscoll has served as Vice President, Finance since June 2017. Ms. Driscoll has more than 25 years of financial leadership experience. Prior to joining Magenta in June 2017 Ms. Driscoll worked at Tokai Pharmaceuticals, Inc., or Tokai, from June 2011 to June 2017 most recently as the vice president of finance from September 2014 to June 2017 where she oversaw all finance and administrative operations for the publicly-traded company, including supporting its 2014 initial public offering. Prior to Tokai, Ms. Driscoll also worked as a financial consultant from July 2005 to June 2011 during which time she served as controller for Gloucester Pharmaceuticals, Inc. now owned by Celgene Corporation and Transmolecular, Inc. now owned by Morphotek, Inc. and supported due diligence efforts related to acquisitions of both companies. Ms. Driscoll earned her undergraduate degree in economics from the State University of New York at Oswego and completed her Master of Business Administration at Suffolk University.- Cindy Driscoll自2017年6月起担任我们的财务Vice President。Driscoll女士拥有超过25年的财务领导经验。在2017年6月加入Magenta之前，Driscoll女士于2011年6月至2017年6月在东海制药（Tokai Pharmaceuticals，Inc.，简称Tokai）工作，最近于2014年9月至2017年6月担任财务Vice President，负责该上市公司的所有财务和行政业务，包括支持其2014年首次公开募股。在加入东海制药之前，Driscoll女士还曾于2005年7月至2011年6月担任财务顾问，在此期间，她曾担任Gloucester Pharmaceuticals，Inc.（现为新基医药公司所有）和Transmolecular，Inc.（现为Morphotek所有）的财务总监，Inc.，并支持与收购两家公司相关的尽职调查工作。Driscoll女士在纽约州立大学奥斯威戈分校（State University of New York at Oswego）获得经济学本科学位，并在萨福克大学（Suffolk University）完成工商管理硕士学位。
- Cindy Driscoll has served as Vice President, Finance since June 2017. Ms. Driscoll has more than 25 years of financial leadership experience. Prior to joining Magenta in June 2017 Ms. Driscoll worked at Tokai Pharmaceuticals, Inc., or Tokai, from June 2011 to June 2017 most recently as the vice president of finance from September 2014 to June 2017 where she oversaw all finance and administrative operations for the publicly-traded company, including supporting its 2014 initial public offering. Prior to Tokai, Ms. Driscoll also worked as a financial consultant from July 2005 to June 2011 during which time she served as controller for Gloucester Pharmaceuticals, Inc. now owned by Celgene Corporation and Transmolecular, Inc. now owned by Morphotek, Inc. and supported due diligence efforts related to acquisitions of both companies. Ms. Driscoll earned her undergraduate degree in economics from the State University of New York at Oswego and completed her Master of Business Administration at Suffolk University.
- Susan Altschuller
Susan Altshuller于2020年8月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席财务官。加入ImmunoGen公司之前，她曾任职Alexion Pharmaceuticals公司，在那里她曾担任投资者关系主管，在那里她曾担任企业财务主管，在那里她曾领导全球财务报告，并提供投资优先级咨询，以支持公司的战略需求。加入Alexion公司之前，她曾担任Bioverativ公司的投资者关系主管，在那里她曾担任华尔街的主要界面，并领导Biogen公司的衍生产品的所有投资者相关活动。在她的职业生涯早期，Altschuller博士在Biogen担任多个职责递增的职位，包括投资者关系、企业融资和商业融资。Altshuller博士拥有伊利诺伊理工学院（Illinois Institute of Technology）的生物医学工程博士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
Susan Altschuller joined ImmunoGen in August 2020 and has served as our Senior Vice President and Chief Financial Officer, since that time. Dr. Altschuller joined ImmunoGen from Alexion Pharmaceuticals, where she served as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company's strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. Dr. Altschuller holds a PhD in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.- Susan Altshuller于2020年8月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席财务官。加入ImmunoGen公司之前，她曾任职Alexion Pharmaceuticals公司，在那里她曾担任投资者关系主管，在那里她曾担任企业财务主管，在那里她曾领导全球财务报告，并提供投资优先级咨询，以支持公司的战略需求。加入Alexion公司之前，她曾担任Bioverativ公司的投资者关系主管，在那里她曾担任华尔街的主要界面，并领导Biogen公司的衍生产品的所有投资者相关活动。在她的职业生涯早期，Altschuller博士在Biogen担任多个职责递增的职位，包括投资者关系、企业融资和商业融资。Altshuller博士拥有伊利诺伊理工学院（Illinois Institute of Technology）的生物医学工程博士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
- Susan Altschuller joined ImmunoGen in August 2020 and has served as our Senior Vice President and Chief Financial Officer, since that time. Dr. Altschuller joined ImmunoGen from Alexion Pharmaceuticals, where she served as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company's strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. Dr. Altschuller holds a PhD in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.
- Aoife Brennan
Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceuticals, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.- Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
- Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceuticals, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.